Citadel Advisors
KZIA

Citadel Advisors’s Kazia Therapeutics KZIA Stock Holding History

Citadel Advisors’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$84K – 14142
2021
Q4 		$84K Buy
+200
New +$99.8K ﹤0.01% 12887

Other funds holding KZIA

BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's KZIA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Kazia Therapeutics (KZIA) in Q2 2026: 28,509 shares worth $401K. The stake represents ﹤0.01% of the portfolio and ranks #10419 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in KZIA as recently as Q3 2024.

Citadel Advisors first reported a position in KZIA in Q1 2014 and has held it in 14 quarters since. 35 funds tracked by Wall St. Rank hold KZIA as of Q2 2026.

  • Citadel Advisors held 28,509 shares of Kazia Therapeutics worth $401K as of Q2 2026.
  • Kazia Therapeutics was a new Citadel Advisors position in Q2 2026.
  • Kazia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10419 holding.
  • Citadel Advisors first reported a position in Kazia Therapeutics in Q1 2014 and has held it in 14 quarters since.
  • 35 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.